BlackRock Group’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$192M Buy
6,134,970
+72,135
+1% +$2.34M 0.09% 259
2016
Q3
$244M Sell
6,062,835
-207,969
-3% -$7.83M 0.12% 200
2016
Q2
$208M Buy
6,270,804
+219,630
+4% +$7.51M 0.11% 231
2016
Q1
$178M Buy
6,051,174
+31,743
+0.5% +$876K 0.1% 250
2015
Q4
$158M Sell
6,019,431
-431,793
-7% -$11.2M 0.09% 258
2015
Q3
$153M Sell
6,451,224
-683,982
-10% -$16.5M 0.09% 254
2015
Q2
$169M Sell
7,135,206
-380,028
-5% -$8.58M 0.09% 253
2015
Q1
$178M Buy
7,515,234
+714,402
+11% +$16M 0.1% 247
2014
Q4
$144M Buy
6,800,832
+427,392
+7% +$8.59M 0.08% 296
2014
Q3
$109M Buy
6,373,440
+232,794
+4% +$3.67M 0.06% 360
2014
Q2
$87.9M Buy
6,140,646
+9,516
+0.2% +$129K 0.05% 413
2014
Q1
$75.8M Sell
6,131,130
-431,436
-7% -$4.98M 0.05% 431
2013
Q4
$71.9M Buy
6,562,566
+344,124
+6% +$3.88M 0.05% 435
2013
Q3
$72.2M Buy
6,218,442
+1,403,412
+29% +$16.4M 0.05% 434
2013
Q2
$53.9M Buy
+4,815,030
New +$57M 0.04% 479

Other funds holding EW

BlackRock Group's EW Position: Q4 2016 in Review

BlackRock Group increased its Edwards Lifesciences (EW) stake by 1.2% in Q4 2016, buying an estimated $2.34M and bringing the position to 6,134,970 shares worth $192M. The position accounts for 0.09% of the portfolio, ranked #259.

BlackRock Group first reported a position in EW in Q2 2013 and has held it in 15 quarters since. The position peaked at $244M in Q3 2016. 686 funds tracked by Wall St. Rank hold EW as of Q4 2016.

  • BlackRock Group held 6,134,970 shares of Edwards Lifesciences worth $192M as of Q4 2016.
  • BlackRock Group bought 72,135 Edwards Lifesciences shares in Q4 2016, an estimated $2.34M.
  • Edwards Lifesciences made up 0.09% of BlackRock Group's portfolio in Q4 2016, its #259 holding.
  • BlackRock Group first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Group's Edwards Lifesciences position peaked at $244M in Q3 2016.
  • 686 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.